Advertisement
Advertisement
CING
Cingulate Inc. Common Stock
5.34
USDSponsored
+0.29
+5.74%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
5.25
-0.09
-1.69%
CING Earnings Reports
Positive Surprise Ratio
CING beat 7 of 18 last estimates.
39%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Cingulate Inc. Common Stock earnings per share and revenue
On May 14, 2026, CING reported earnings of -0.95 USD per share (EPS) for Q1 26, missing the estimate of -0.45 USD, resulting in a -108.52% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -10.77% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Edgewise Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.53
Surprise
-10.55%
Denali Therapeutics Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.66
Actual
-$0.68
Surprise
-1.51%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
FAQ
What were Cingulate Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Cingulate Inc. Common Stock reported EPS of -$0.95, missing estimates by -108.52%, and revenue of $0.00, 0% as expectations.
How did the market react to Cingulate Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -10.77%, changed from $4.92 before the earnings release to $4.39 the day after.
When is Cingulate Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Cingulate Inc. Common Stock's next earnings report?
Based on --
analysts, Cingulate Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement